Advances in Topical and Systemic Antifungals

Dermatologic Clinics

Volumn 25, Issue 2, 2007, Pages 165-183

  Zhang, Alexandra Y ^a   Camp, William L ^b   Elewski, Boni E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASTEMIZOLE; BUTENAFINE; CASPOFUNGIN; CICLOPIROX; CISAPRIDE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; HALOPROGIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NAFTIFINE; NYSTATIN; OXICONAZOLE; POSACONAZOLE; RAVUCONAZOLE; SELENIUM SULFIDE; TERBINAFINE; TERFENADINE; THIOCARBONIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASPERGILLOSIS; BLASTOMYCOSIS; BURNING SENSATION; CANDIDEMIA; CANDIDIASIS; CARDIOTOXICITY; CHILL; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; ERYTHEMA; ERYTHEMA MULTIFORME; FACE EDEMA; FATIGUE; FEVER; FLUSHING; GASTRITIS; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEMOLYTIC ANEMIA; HEPATITIS; HISTOPLASMOSIS; HUMAN; HYPERCALCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; IMPOTENCE; INVASIVE CANDIDIASIS; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG INFILTRATE; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; PAIN; PAPULE; PERIPHERAL EDEMA; PHLEBITIS; PHOTOPHOBIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN URINE LEVEL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; SEBORRHEIC DERMATITIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN FISSURE; SKIN IRRITATION; SKIN MACERATION; SKIN TINGLING; SOMNOLENCE; SOUTH AMERICAN BLASTOMYCOSIS; STEVENS JOHNSON SYNDROME; SUICIDE ATTEMPT; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYPNEA; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THRUSH; TINEA CAPITIS; TINEA CORPORIS; TINEA PEDIS; TINEA VERSICOLOR; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VAGINA CANDIDIASIS; VASODILATATION; VISUAL DISORDER; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS; ONYCHOMYCOSIS;

EID: 34047269303     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.01.002     Document Type: Review

References (93)

1. Georgopapadakou N.H. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1 5 (1998) 547-557
2. Hazen E.L., and Brown R. Two antifungal agents produced by a soil actinomycete. Science 112 2911 (1950) 423
3. Hazen E.L., and Brown R. Nystatin. Ann N Y Acad Sci 89 (1960) 258-266
4. Bennett J.E. Antimicrobial agents: antifungal agents. In: Gilaman A.G., and Nies A.S. (Eds). The pharmacological basis of therapeutics (1993), McGraw-Hill, New York 1165-1181
5. Kuriyama T., Williams D.W., Bagg J., et al. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 20 6 (2005) 349-353
6. Wasilewski Jr. C. Allergic contact dermatitis from nystatin. Arch Dermatol 102 2 (1970) 216-217
7. Garty B.Z. Stevens-Johnson syndrome associated with nystatin treatment. Arch Dermatol 127 5 (1991) 741-742
8. Epstein J.B., Truelove E.L., Hanson-Huggins K., et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer 12 7 (2004) 517-525
9. Gold W., Stout H.A., Pagano J.F., et al. Amphotericins A and B, antifungal anitbiotics produced by streptomycete I in vitro studies. Antibiotics Ann 3 (1955) 579-586
10. Ng A.W., Wasan K.M., and Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 6 1 (2003) 67-83
11. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49 Suppl 1 (2002) 7-10
12. Girois S.B., Chapuis F., Decullier E., et al. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 25 2 (2006) 138-149
13. Kleinberg M. What is the current and future status of conventional amphotericin B?. Int J Antimicrob Agents 27 Suppl 1 (2006) 12-16
14. Buchel K.H., Draber W., Regel E., et al. Synthesis and properties of clotrimazole and other antimycotic 1-triphenylmethylimidazoles. Arzneimittelforschung 22 8 (1972) 1260-1272
15. Holt R.J., and Newman R.L. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol 25 12 (1972) 1089-1097
16. Clayton Y.M., and Connor B.L. Comparison of clotrimazole cream, Whitfield's ointment and nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 89 3 (1973) 297-303
17. Rajan V.S., and Thirumoorthy T. Treatment of cutaneous candidiasis: a double blind, parallel comparison of sulconazole nitrate 1% cream and clotrimazole 1% cream. Australas J Dermatol 24 1 (1983) 33-36
18. Godefroi E.F., Heeres J., Van Cutsem J., et al. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 12 5 (1969) 784-791
19. Heel R.C., Brogden R.N., Speight T.M., et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 16 3 (1978) 177-201
20. Bigardi A.S., Pigatto P.D., and Altomare G. Allergic contact dermatitis due to sulconazole. Contact Dermatitis 26 4 (1992) 281-282
21. Grant S.M., and Clissold S.P. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39 6 (1990) 877-916
22. Fluconazole [package insert]. New York: Pfizer Roerig; 1997.
23. Pham C.P., de Feiter P.W., van der Kuy P.H., et al. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 40 7-8 (2006) 1456-1461
24. Gussenhoven M.J., Haak A., Peereboom-Wynia J.D., et al. Stevens-Johnson syndrome after fluconazole. Lancet 338 8759 (1991) 120
25. Yu D.T., Peterson J.F., Seger D.L., et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 14 11 (2005) 755-767
26. Gupta A.K., Sauder D.N., and Shear N.H. Antifungal agents: an overview. Part II. J Am Acad Dermatol 30 6 (1994) 911-933 [quiz: 34-6]
27. Itraconazole [package insert]. Titusville (NJ): Janssen; 1996.
28. Gupta A.K., Sibbald R.G., Lynde C.W., et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 36 3 Pt 1 (1997) 395-402
29. Gupta A.K., Alexis M.E., Raboobee N., et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol 137 2 (1997) 251-254
30. Doncker P.D., Gupta A.K., Marynissen G., et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 37 6 (1997) 969-974
31. Heeres J., Backx L.J., Mostmans J.H., et al. Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 22 8 (1979) 1003-1005
32. Mahler C., Verhelst J., and Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71 3 Suppl (1993) 1068-1073
33. Nizoral tablets [package insert]. Titusville (NJ): Janssen Pharmaceutica; 2001.
34. Odds F.C., Milne L.J., Gentles J.C., et al. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother 6 1 (1980) 97-104
35. Lester M. Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corporis. Cutis 55 3 (1995) 181-183
36. Gupta A.K., Sauder D.N., and Shear N.H. Antifungal agents: an overview. Part I. J Am Acad Dermatol 30 5 Pt 1 (1994) 677-698 [quiz: 698-700]
37. Fothergill A.W. Miconazole: a historical perspective. Expert Rev Anti Infect Ther 4 2 (2006) 171-175
38. Van Cutsem J.M., and Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 17 6 (1972) 392-404
39. Dooms-Goossens A., Matura M., Drieghe J., et al. Contact allergy to imidazoles used as antimycotic agents. Contact Dermatitis 33 2 (1995) 73-77
40. Elewski B.E., Jones T., and Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Cutis 58 4 (1996) 305-307
41. Jegasothy B.V., and Pakes G.E. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. Clin Ther 13 1 (1991) 126-141
42. Vfend [package insert]. New York: Pfizer Roerig; 2003.
43. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2 4 (2004) 485-497
44. Heyn K., Tredup A., Salvenmoser S., et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp and Fusarium solani. Antimicrob Agents Chemother 49 12 (2005) 5157-5159
45. Racette A.J., Roenigk Jr. H.H., Hansen R., et al. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 52 5 Suppl 1 (2005) S81-S85
46. Boucher H.W., Groll A.H., Chiou C.C., et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64 18 (2004) 1997-2020
47. Korting H.C., and Grundmann-Kollmann M. The hydroxypyridones: a class of antimycotics of its own. Mycoses 40 7-8 (1997) 243-247
48. Abrams B.B., Hanel H., and Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 9 4 (1991) 471-477
49. Aly R., Maibach H.I., Bagatell F.K., et al. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin Ther 11 3 (1989) 290-303
50. Ciclopirox olamine. Physician's desk reference (1999), Medical Economics Company, Montvale (NJ) 1327
51. Bogaert H., Cordero C., Ollague W., et al. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 14 4 (1986) 210-216
52. Jue S.G., Dawson G.W., and Brogden R.N. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 29 4 (1985) 330-341
53. Oxford A.E., Raistrick H., Simonart P., et al. Studies in the biochemistry of micro-organisms: Griseofulvin, C(17)H(17)O(6)C1, a metabolic product of Peincillium griseofulvum Dierckx. Mycoses 49 3 (2006) 232-235
54. Tanz R.R., Hebert A.A., and Esterly N.B. Treating tinea capitis: should ketoconazole replace griseofulvin?. J Pediatr 112 6 (1988) 987-991
55. Dragos V., and Lunder M. Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Pediatr Dermatol 14 1 (1997) 46-48
56. Bennett M.L., Fleischer A.B., Loveless J.W., et al. Oral griseofulvin remains the treatment of choice for tinea capitis in children. Pediatr Dermatol 17 4 (2000) 304-309
57. Cote J. Interaction of griseofulvin and oral contraceptives. J Am Acad Dermatol 22 1 (1990) 124-125
58. Ryder N.S., and Dupont M.C. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J 230 3 (1985) 765-770
59. Ryder N.S. Squalene epoxidase as a target for the allylamines. Biochem Soc Trans 19 3 (1991) 774-777
60. Monk J.P., and Brogden R.N. Naftifine: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 42 4 (1991) 659-672
61. Millikan L.E., Galen W.K., Gewirtzman G.B., et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 18 1 Pt 1 (1988) 52-56
62. Roberts D.T. Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Dermatology 194 Suppl 1 (1997) 37-39
63. Kovarik J.M., Kirkesseli S., Humbert H., et al. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 126 Suppl 39 (1992) 8-13
64. Faergemann J., Zehender H., and Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 19 2 (1994) 121-126
65. Petranyi G., Meingassner J.G., and Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 31 9 (1987) 1365-1368
66. Shadomy S., Espinel-Ingroff A., and Gebhart R.J. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 23 2 (1985) 125-132
67. Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol 14 2 (1989) 114-115
68. Bergstresser P.R., Elewski B., Hanifin J., et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens. J Am Acad Dermatol 28 4 (1993) 648-651
69. Evans E.G., Dodman B., Williamson D.M., et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 307 6905 (1993) 645-647
70. Vermeer B.J., Staats C.C., and van Houwelingen J.C. [Terbinafine versus miconazole in patients with tinea pedis]. Ned Tijdschr Geneeskd 140 31 (1996) 1605-1608
71. Savin R.C. Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine. J Am Acad Dermatol 23 4 Pt 2 (1990) 786-789
72. Alpsoy E., Yilmaz E., and Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 23 4 (1996) 259-262
73. Tausch I., Decroix J., Gwiezdzinski Z., et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol 37 2 (1998) 140-142
74. Villars V., and Jones T.C. Clinical efficacy and tolerability of terbinafine (Lamisil): a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 14 2 (1989) 124-127
75. Darkes M.J., Scott L.J., and Goa K.L. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 4 1 (2003) 39-65
76. Lesher Jr. J.L., Babel D.E., Stewart D.M., et al. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. J Am Acad Dermatol 36 2 Pt 1 (1997) S20-S24
77. Maeda T., Takase M., Ishibashi A., et al. Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent. Yakugaku Zasshi 111 2 (1991) 126-137
78. Syed T.A., and Maibach H.I. Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Expert Opin Pharmacother 1 3 (2000) 467-473
79. Savin R., De Villez R.L., Elewski B., et al. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. J Am Acad Dermatol 36 2 Pt 1 (1997) S15-S19
80. Odds F.C., Brown A.J., and Gow N.A. Antifungal agents: mechanisms of action. Trends Microbiol 11 6 (2003) 272-279
81. Stone J.A., Holland S.D., Wickersham P.J., et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 46 3 (2002) 739-745
82. Graybill J.R., Bocanegra R., Luther M., et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 41 9 (1997) 1937-1939
83. Graybill J.R., Najvar L.K., Luther M.F., et al. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother 41 8 (1997) 1775-1777
84. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 25 (2002) 2020-2029
85. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 14 (2004) 1391-1402
86. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 11 (2004) 1563-1571
87. MSD Sharp & Dohme Ltd. Caspofungin MSD: summary of product characteristics. Available at: http://www.eudra.org, 2004.
88. Maschmeyer G., and Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 48 4 (2005) 227-234
89. Hiemenz J, Simpson D, Devine S, et al. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract 1648]. San Francisco (CA), September 26-29, 1999.
90. Mukai T, Nakahara K, Takaya T, et al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and nonelderly subjects. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 16-19, 2001.
91. Ostrosky-Zeichner L, Anaissie E, Kontoyiannia D, et al. Micafungin (MCFG), an echinocandin antifungal agent for the treatment of new and refractory candidemia [abstract P-35]. Presented at the 13th Annual Focus on Fungal Infections Meeting. Maui (HI), Mar 19-21, 2003.
92. Kohno S, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycosis in Japan [abstract]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Dec 16-19, 2001.
93. Powles R., Chopra R., et al. Assessment of maximum tolerated dose and pharmacokinetics of FK463 in neutropenic patients after haematopoietic stem cell transplantation. [abstract]. Blood 98 Pt 2 (2001) 361